$AIM

HEMISPHERX BIOPHARMA INC

CIK:0000946644|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenues:
Clinical treatment programs - US	$ 26	$ 25	$ 48	$ 41
Total Revenues	26	25	48	41
Costs and Expenses:
Production costs	5	10	9	20
Research and development	589	1,174	1,071	2,254
General and administrative	2,945	1,487	4,707	4,032
Total Costs and Expenses	3,539	2,671	5,787	6,306
Operating loss	(3,513)	(2,646)	(5,739)	(6,265)
Gain (Loss) on investments	(1)	(9)	(2)	18
Interest and other income	21	10	29	21
Interest expense and other finance costs	(295)	(149)	(631)	(273)
Loss on change in fair value of warrant liability			(468)
Net Loss	$ (3,788)	$ (2,794)	$ (6,811)	$ (6,499)
Basic loss per share	$ (0.43)	$ (3.68)	$ (0.96)	$ (8.88)
Diluted loss per share	$ (0.43)	$ (3.68)	$ (0.96)	$ (8.88)
Weighted average shares outstanding basic	17,118,695	759,289	10,819,484	731,650
Weighted average shares outstanding diluted	17,118,695	759,289	10,819,484	731,650

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Cash flows from operating activities:
Net loss	$ (3,788)	$ (3,023)	$ (2,794)	$ (3,705)	$ (6,811)	$ (6,499)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and Amortization					571	377
Abandonment and expiration of patents and trademark rights					24	615
Equity-based compensation						60
Gain on sale of marketable investments						(18)
Change in fair value of warrants					468
Loss on issuance of warrants					32
Change in assets and liabilities:
Prepaid expenses and other assets					(121)	770
Lease liability					(120)	(78)
Accounts payable and Accrued Expenses					(1,359)	881
Other receivables					7
Net cash used in operating activities					(7,309)	(3,892)
Cash flows from investing activities:
Proceeds from sale of marketable investments					4	2,026
Purchase of marketable investments					(6)	(91)
Purchase of patent and trademark rights					(147)	(283)
Net cash (used in) provided by investing activities					(149)	1,652
Cash flows from financing activities:
Proceeds from sale of stock, net of issuance costs					2,538	765
Proceeds from note payable, net of issuance costs						250
Proceeds from warrant exercise					5,733
Repayment of debt obligation					(821)
Proceeds from Registered Direct Offerings					5,293
Proceeds from Rights Offering					1,630
Net cash provided by financing activities					14,373	1,015
Net increase (decrease) in cash and cash equivalents					6,915	(1,225)
Cash and cash equivalents at beginning of period		$ 2,985		$ 1,701	2,985	1,701	$ 1,701
Cash and cash equivalents at end of period	$ 9,900		$ 476		9,900	476	$ 2,985
Supplemental disclosures of non-cash investing and financing cash flow information:
Unrealized gain on marketable investments						85
Repayment of debt obligation with shares					$ 400	$ 421

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 9,900	$ 2,985
Marketable investments	64	62
Other receivables		7
Prepaid expenses and other current assets	468	241
Total current assets	10,432	3,295
Property and equipment, net	54	71
Right of use asset, net	260	378
Patent and trademark rights, net	1,714	1,661
Other assets	271	377
Total assets	12,731	5,782
Current liabilities:
Accounts payable	480	1,630
Accrued expenses	586	795
Current portion of operating lease liability	259	250
Current portion of note payable, net	3,621	3,549
Total current liabilities	4,946	6,224
Long-term liabilities:
Operating lease liability	41	170
Long-term note payable		927
Warrant liability		8,244
Total liabilities	4,987	15,565
Commitments and contingencies (Note 10)
Stockholders’ equity (deficit):
Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 28,990,073 and 3,069,875 as of June 30, 2026 and December 31, 2025, respectively	29	3
Additional paid-in capital	455,312	431,000
Accumulated deficit	(447,597)	(440,786)
Total stockholders’ equity (deficit)	7,744	(9,783)
Total liabilities and stockholders’ equity	12,731	5,782
Series A Junior Participating Preferred Stock [Member]
Stockholders’ equity (deficit):
Preferred Stock value
Series B Convertible Preferred Stock [Member]
Stockholders’ equity (deficit):
Preferred Stock value
Series G Convertible Preferred Stock [Member]
Stockholders’ equity (deficit):
Preferred Stock value